Intrinsic Value of S&P & Nasdaq Contact Us

Femasys Inc. FEMY NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
41/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Femasys Inc. (FEMY) — Analyst outlook / Analyst consensus target is. Based on 5 analyst ratings, the consensus is bullish — 5 Buy.

Analysts estimate Earnings Per Share (EPS) of $-0.80 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-0.85 vs est $-0.80 (missed -5.9%). 2025: actual $-0.47 vs est $-0.52 (beat +10.2%). Analyst accuracy: 92%.

FEMY Analyst Ratings

Buy
5
Ratings
5 Buy
Based on 5 analysts giving stock ratings to Femasys Inc. in the past 3 months
Rating breakdown
Buy
5 100%
100%
Buy
5 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — FEMY

92%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual –$0.85 vs Est –$0.80 ▼ 5.6% off
2025 Actual –$0.47 vs Est –$0.52 ▲ 11.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.

Revenue Estimates — FEMY

61%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024 Actual $0.002B vs Est $0.003B ▼ 66.5% off
2025 Actual $0.002B vs Est $0.003B ▼ 11.0% off
Revenue Trend
Revenue has been relatively flat. Analysts forecast significant revenue growth ahead.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message